JP2003522724A5 - - Google Patents

Download PDF

Info

Publication number
JP2003522724A5
JP2003522724A5 JP2000543139A JP2000543139A JP2003522724A5 JP 2003522724 A5 JP2003522724 A5 JP 2003522724A5 JP 2000543139 A JP2000543139 A JP 2000543139A JP 2000543139 A JP2000543139 A JP 2000543139A JP 2003522724 A5 JP2003522724 A5 JP 2003522724A5
Authority
JP
Japan
Prior art keywords
acid
carboxylic acid
group
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000543139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522724A (ja
Filing date
Publication date
Priority claimed from US09/057,260 external-priority patent/US5962488A/en
Application filed filed Critical
Publication of JP2003522724A publication Critical patent/JP2003522724A/ja
Publication of JP2003522724A5 publication Critical patent/JP2003522724A5/ja
Pending legal-status Critical Current

Links

JP2000543139A 1998-04-08 1998-11-16 医薬製剤のための酸化防止剤−安定剤系 Pending JP2003522724A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/057,260 1998-04-08
US09/057,260 US5962488A (en) 1998-04-08 1998-04-08 Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
PCT/US1998/024471 WO1999052529A1 (en) 1998-04-08 1998-11-16 Antioxidant stabilizer system for pharmaceutical formulations

Publications (2)

Publication Number Publication Date
JP2003522724A JP2003522724A (ja) 2003-07-29
JP2003522724A5 true JP2003522724A5 (https=) 2006-01-05

Family

ID=22009506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000543139A Pending JP2003522724A (ja) 1998-04-08 1998-11-16 医薬製剤のための酸化防止剤−安定剤系

Country Status (7)

Country Link
US (2) US5962488A (https=)
EP (1) EP1067927B1 (https=)
JP (1) JP2003522724A (https=)
AT (1) ATE318598T1 (https=)
CA (1) CA2327708A1 (https=)
DE (1) DE69833684T2 (https=)
WO (1) WO1999052529A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
WO2000042997A1 (en) * 1999-01-21 2000-07-27 Shionogi & Co., Ltd. Medicinal compositions retarded in the discoloration of phenolic hydroxyl compounds
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007046411A1 (ja) * 2005-10-19 2007-04-26 Dainippon Sumitomo Pharma Co., Ltd. イソキサゾール化合物の安定化方法
DE102007025275A1 (de) * 2007-05-31 2008-12-04 Qiagen Gmbh Butendisäure oder deren Derivate zur Behandlung einer biologischen Probe
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
EP2309985B1 (en) * 2008-07-28 2018-03-14 Takeda Pharmaceutical Company Limited Pharmaceutical composition
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
TWI473628B (zh) * 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
BR112017027855B1 (pt) * 2015-06-23 2022-11-16 Intervet International B.V. Composição farmacêutica, seu uso, água potável medicamentosa e método para sua preparação
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP4221704B1 (en) * 2020-10-01 2025-09-24 Imago Biosciences Inc. Pharmaceutical formulations for treating diseases mediated by kdm1a

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB679192A (en) * 1948-07-09 1952-09-17 Eastman Kodak Co Method of stabilizing fats and fatty oils against oxidation
GB682205A (en) * 1949-03-16 1952-11-05 Eastman Kodak Co Improvements in and relating to anti-oxidants for oils and fats
US4091091A (en) * 1973-11-08 1978-05-23 Eli Lilly And Company Stabilized nitroglycerin tablets
JPS5299242A (en) * 1976-02-12 1977-08-19 Tanabe Seiyaku Co Antiioxidant
JPS62153385A (ja) * 1985-12-27 1987-07-08 Riken Vitamin Co Ltd 酸化防止剤
US4837031A (en) * 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
DK0471515T3 (da) * 1990-08-15 1997-07-21 Lilly Co Eli Ringsubstituerede 2-amino-1,2,3,4-tetrahydronphtalener, 3-aminochromaner og 3-aminothiochromaner
US5077069A (en) * 1991-01-07 1991-12-31 Kabi Pharmacia Ab Composition of natural antioxidants for the stabilization of polyunsaturated oils
JPH06500594A (ja) * 1991-01-07 1994-01-20 カビ　ファルマシア　アクチェボラーグ 多不飽和油の安定化のための天然酸化防止剤の組成物
JPH05339154A (ja) * 1992-06-03 1993-12-21 Sagami Chem Res Center 肝機能改善剤
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
JPH0717855A (ja) * 1992-09-02 1995-01-20 Maruha Corp 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
CA2173467A1 (en) * 1993-10-25 1995-05-04 Keith D. Ertel A stable pharmaceutical composition of terfenadine and ibuprofen
JPH09194362A (ja) * 1996-01-19 1997-07-29 Bizen Kasei Kk ドコサヘキサエン酸及びエイコサペンタエン酸含有リン脂質を含む組成物
JP3941073B2 (ja) * 1996-03-01 2007-07-04 日本油脂株式会社 油脂組成物及びそれを含む食品
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives

Similar Documents

Publication Publication Date Title
JP2003522724A5 (https=)
EP1067927A4 (en) ANTIOXIDANT STABILIZER SYSTEM FOR PHARMACEUTICAL FORMULATIONS
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
PL362443A1 (en) Mixtures or organic compounds for the treatmentof airway diseases
JP2001526218A5 (https=)
IL101162A0 (en) Pharmaceutical compositions for oral administration comprising an indole derivative
RU98115774A (ru) Новые производные 19-нор-прегнена
PT1642885E (pt) Utilização de uma composição farmacêutica contendo um derviado de ácido para-aminofenilacético para o tratamento de estados inflamatórios do tracto gastrointestinal
RU2001111880A (ru) Композиции для перорального введения, содержащие луфенурон и нитенпирам, для борьбы с блохами
KR960041168A (ko) 베타-아드레날린 효능성 작용물질
JP2002519425A5 (https=)
DE60121145D1 (de) Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln
KR0180232B1 (ko) 수난용성 약제를 함유하는 약학 조성물
HU9600266D0 (en) Pharmaceutical organic salt solutions for endonasal application
SE9901573D0 (sv) New compounds
KR920002579A (ko) 종양치료 조성물 및 치료방법
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
JP2003519228A5 (https=)
MY125099A (en) Comminuted form of (s)-2-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) penyl] propanoic acid
JP2002539089A5 (https=)
KR900016135A (ko) 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
RU94044357A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования увеличения веса, индуцирования снижения веса или ингибирования аппетита
TR200103144T2 (tr) Yeni bileşikler
IL148196A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same